产品说明书

Cisplatin

Print
Chemical Structure| 15663-27-1 同义名 : 顺-二胺二氯铂(II) ;cis-Platinum;CDDP;CACP;cis-Diamminedichloroplatinum;DDP;cis DDP;cis-diamminedichloroplatinum II;NSC 119875;cis-Diaminodichloroplatinum
CAS号 : 15663-27-1
货号 : A210558
分子式 : Cl2H6N2Pt
纯度 : 99%
分子量 : 300.05
MDL号 : MFCD00011623
存储条件:

粉末 Inert atmosphere,Room Temperature

液体 -20°C:3-6个月-80°C:12个月

溶解度 :

H2O: 1 mg/mL(3.33 mM),配合低频超声,并水浴加热至45℃助溶

DMF: 10 mg/mL(33.33 mM),配合低频超声助溶

动物实验配方:

PO 0.5% CMC-Na 85 mg/mL suspension

生物活性
靶点
  • DNA synthesis

描述 Cisplatin (CDDP) is an antineoplastic chemotherapy agent, primarily by forming cross-links with DNA and thus inflicting DNA damage within cancer cells. Cisplatin triggers ferroptosis and induce autophagy, contributing to its effectiveness against various cancer types[1].[2].[3].
临床研究
NCT号 适应症或疾病 临床期 招募状态 预计完成时间 地点
NCT02128282 Cholangiocarcinoma Phase 1 Phase 2 Recruiting November 2021 United States, Arizona ... 展开 >> Mayo Clinic Recruiting Scottsdale, Arizona, United States, 85259-5499 Contact: Mayo Clinic Clinical Trials Office    855-776-0015       Principal Investigator: Mitesh Borad, M.D.          United States, Colorado University of Colorado- Denver Recruiting Aurora, Colorado, United States, 80045 Contact: Amy Szilard    720-848-0702    Amy.Szilard@ucdenver.edu    Principal Investigator: Sarah (Lindsey) Davis, MD          United States, Florida Mayo Clinic Recruiting Jacksonville, Florida, United States, 32224 Contact: Mayo Clinic Clinical Trials Office    855-776-0015       Principal Investigator: Kabir Mody, MD          United States, Minnesota Mayo Clinic Recruiting Rochester, Minnesota, United States, 55905 Contact: Mayo Clinic Clinical Trials Office    855-776-0015       Principal Investigator: Joleen Hubbard, MD          United States, Texas Texas Oncology - Baylor Charles A. Sammons Cancer Center Recruiting Dallas, Texas, United States, 75246 Contact: Tammy Carmical, RN    214-370-1937    tammy.carmical@usoncology.com    Principal Investigator: Carlos Becerra, M.D.          Texas Oncology-Tyler Recruiting Tyler, Texas, United States, 75702 Contact: Karen Poe, RN    903-579-9869    karen.poe@usoncology.com    Principal Investigator: Donald A Richards, M.D.          Korea, Republic of Asan Medical Center Recruiting Seoul, Songpa-gu, Korea, Republic of, 138-736 Contact: Heung-Moon Chang, MD    82-3010-3219 ext 3210    changhm@amc.seoul.kr    Contact: Seok kyung Jeong    82-2-3010-5634    jsk0213@amc.seoul.kr    Samsung Medical Center Recruiting Seoul, Korea, Republic of Contact: Eunyou Lee    82-2-3410-0955    ley0709@samsung.com    Principal Investigator: Joon Oh Park, MD          Seoul National University Hospital Recruiting Seoul, Korea, Republic of Contact: Myoungsun Choi    82-2-2072-7612    iamyou3@hanmail.net    Principal Investigator: Do-Youn Oh, MD          Severance Hospital, Yonsei University Health System Recruiting Seoul, Korea, Republic of Contact: So Young Hwang    82-2-2228-8180    syhwang@yuhs.ac    Principal Investigator: Sun Young Rha, MD          Taiwan China Medical University Hospital Recruiting Taichung City, Taiwan Contact: Pei-Chen Hsu    +886-4-2205-2121    peggyshiu0807@gmail.com    Principal Investigator: Li-Yuan Bai, M.D. 收起 <<
NCT00915382 Advanced Gastric Cancer Phase 3 Completed - Korea, Republic of ... 展开 >> Department of Oncology, Asan Medical Center Seoul, Korea, Republic of, 138-736 收起 <<
NCT03427359 Nasopharyngeal Carcinoma Phase 2 Completed - -
实验方案
1mg 5mg 10mg

1 mM

5 mM

10 mM

3.33mL

0.67mL

0.33mL

16.66mL

3.33mL

1.67mL

33.33mL

6.67mL

3.33mL

参考文献

[1]Wang X, et al. Requirement for ERK activation in cisplatin-induced apoptosis. J Biol Chem. 2000 Dec 15;275(50):39435-43.

[2]Cummings BS, et al. Cisplatin-induced renal cell apoptosis: caspase 3-dependent and -independent pathways. J Pharmacol Exp Ther. 2002 Jul;302(1):8-17.

[3]Park HR, et al. Enhanced antitumor efficacy of cisplatin in combination with HemoHIM in tumor-bearing mice. BMC Cancer. 2009 Mar 17;9:85.

[4]Shimeda Y, et al. Protective effects of capsaicin against cisplatin-induced nephrotoxicity in rats. Biol Pharm Bull. 2005 Sep;28(9):1635-8.